Archive · 8 Jan 2026
Gland Pharma Gains FDA Approval for Ophthalmic Solution
Gland Pharma, a company that makes medicines, got permission from the US FDA to sell a new eye drop medicine.
This medicine helps with itchy eyes caused by allergies.
It's the same as another medicine called Pataday, but now people can buy it without a prescription.
This is good news for Gland Pharma because it shows they can make high-quality eye medicines.
After the news, the company's stock price went up a little.
Gland Pharma received FDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7%.
The product is an over-the-counter alternative to Pataday Once Daily Relief 0.7% for treating ocular itching due to allergic conjunctivitis.
This approval strengthens Gland Pharma's position in the ophthalmic segment.
The company's shares closed at ₹1,710 on January 7, up 0.99%.
This milestone highlights Gland Pharma's focus on developing high-quality ophthalmic formulations.
- Who
- Gland Pharma Limited
- What
- Received FDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7%
- When
- January 7
- Where
- United States
- Why
- To market a therapeutically equivalent product for treating ocular itching associated with allergic conjunctivitis
- Company
- Gland Pharma Limited
- Product
- Olopatadine Hydrochloride Ophthalmic Solution 0.7%
- Approval Authority
- US Food and Drug Administration (FDA)
- Therapeutic Equivalent
- Pataday Once Daily Relief 0.7%
- Indication
- Treatment of ocular itching associated with allergic conjunctivitis
- Market Impact
- Strengthens Gland Pharma's position in the ophthalmic segment
- Stock Price Change
- ₹1,710 (up ₹16.70 or 0.99%)
